These two could become direct competitors relatively soon.…
SRPT earnings call for the period ending June 30, 2024.…
Sarepta Therapeutics falls on revenue miss, weak outlook…
One companys negative results can increase scrutiny of anothers work.…
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von der Citigroup:
Die Analysten der Citigroup stufen die Aktie des Biopharma-Unternehmens Sarepta Therapeutics Inc.…
New York (www.aktiencheck.de) - Rating-Update:
Gavin Clark-Gartner, Analyst von Evercore ISI, stuft die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN:…
New York (www.aktiencheck.de) - Rating-Update:
Die Analysten von Morgan Stanley stufen die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN: A1J1BH,…
Boston, MA (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Leerink Partners:
Die Analysten von Leerink Partners erhöhen in einer aktuellen Aktienanalyse ihr Kursziel…
New York (www.aktiencheck.de) - Rating-Update:
Die Analysten von Goldman Sachs bewerten die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN: A1J1BH,…
Toronto (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von BMO Capital Markets:
Die Analysten von BMO Capital Markets erhöhen in einer aktuellen Aktienanalyse ihr…
New York (www.aktiencheck.de) - Rating-Update:
Die Analysten von Needham & Co stufen die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN:…
Toronto (www.aktiencheck.de) - Rating-Update:
Die Analysten vom Investmenthaus RBC Capital Markets stufen die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN:…
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
Charlotte (www.aktiencheck.de) - Rating-Update:
Tazeen Ahmad, Analyst von BofA Securities, stuft die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN: A1J1BH,…
…
…
These are the stocks posting the largest moves in midday trading.…
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares soared almost 35% after the US Food and Drug Administration (FDA) approved the expanded use…
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares soared almost 35% after the US Food and Drug Administration (FDA) approved the expanded use…
Frankfurt (www.aktiencheck.de) - Sarepta Therapeutics legt nach FDA-Zulassung stark zu - Aktiennews
Sarepta Therapeutics (ISIN: US8036071004, WKN: A1J1BH, Ticker-Symbol: AB3A, NASDAQ-Symbol:…
These are the stocks posting the largest moves in premarket trading.…
• Sarepta Therapeutics erhält erweiterte FDA-Zulassung • Zusammenarbeit mit Roche bei Medikament gegen Muskelschwund • Sarepta Therapeutics-Aktie mit Kurssprung …
The Nasdaq and S&P 500 fell from record highs Thursday. Sarepta Therapeutics surged Friday on FDA approval.…
The Dow, S&P 500, and Nasdaq were little changed at midday Friday, June 21, 2024 as reports showed existing home…
Kulmbach (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse vom Online-Anlegermagazin "Der Aktionär":
Michel Doepke von "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die des…
Sarepta Therapeutics surges 36% after-hours following expanded FDA approval…
…
Sarepta Therapeutics gains as Pfizer failure removes overhang…
London (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Barclays:
Gena Wang, Analystin von Barclays, nimmt in einer aktuellen Aktienanalyse die Aktie von Sarepta…
…
Mizuho raises Sarepta Therapeutics stock target on FDA hopes…
SRPT earnings call for the period ending March 31, 2024.…
…
…
…
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…
The upcoming regulatory decision on its latest drug could be big.…
UBS raises Sarepta Therapeutics shares target on label outlook…
SRPT earnings call for the period ending December 31, 2023.…
…
The companys hyperfocus on its core area could continue to be highly lucrative.…
Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.…
Its always tough to be compared to a giant.…
…
One pundit feels there is solid potential in one of the companys more recently approved drugs.…
…
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…
Sarepta Therapeutics shares rally, Mizuho says confidence in label expansion remains unwavering…
…
Both develop medicines for rare diseases, and each aims to conquer a niche market.…